Kairos Pharma to Present at H.C. Wainwright Global Investment Conference

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced that CEO and Chairman John Yu, MD, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, at the Lotte New York Palace Hotel in New York. This presentation provides investors and the medical community with crucial insights into the company's progress in developing innovative cancer therapeutics.

The company's lead candidate, ENV105, represents a significant advancement in oncology treatment by targeting CD105, a protein identified as a key driver of resistance to various cancer treatments. CD105 elevation in response to standard therapy often results in resistance and disease relapse, making ENV105's mechanism of action particularly important for improving cancer treatment outcomes. By targeting CD105, ENV105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.

ENV105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, addressing substantial unmet medical needs in these patient populations. The company utilizes structural biology to overcome drug resistance and immune suppression in cancer, positioning itself at the forefront of oncology therapeutics development. Investors can access the latest news and updates relating to KAPA through the company's newsroom at https://ibn.fm/KAPA.

The presentation at this prestigious investment conference matters because it provides visibility into potentially transformative cancer treatments that could address the critical challenge of drug resistance. Cancer drug resistance remains a major obstacle in oncology, leading to treatment failure and disease progression in many patients. Kairos Pharma's approach to targeting CD105 could offer new hope for patients who have developed resistance to standard therapies, potentially improving survival rates and quality of life for cancer patients worldwide.

The conference presentation also highlights the growing importance of biopharmaceutical companies working on innovative solutions to complex medical challenges. For the industry, successful development of ENV105 could establish new treatment paradigms for managing drug resistance in cancer therapy. The full press release detailing the conference presentation is available at https://ibn.fm/mdybH.